

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Professor Mark Boguniewicz MD**

Professor, Division of Allergy-Immunology

Department of Pediatrics

National Jewish Health and University of Colorado School of Medicine, USA

Professor Mark Boguniewicz, is a professor in the Division of Allergy-Immunology, Department of Pediatrics, at National Jewish Health and University of Colorado School of Medicine. He completed his residency in pediatrics at Children's Hospital of Michigan and fellowship in allergy-immunology and rheumatology at Children's Hospital and Harvard Medical School in Boston. He is board certified in pediatrics and allergy-immunology.

Professor Boguniewicz is a Fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), past Chair of the Dermatologic and Ocular Diseases Interest Section and past Chair of the Eczema Committee. He is also a Fellow of the American College of Allergy, Asthma, and Immunology (ACAAI). He is on the editorial board of *Journal of Allergy and Clinical Immunology: In Practice*. He served on the Joint Taskforce on Topical Calcineurin Inhibitors of the AAAAI and ACAAI and was co-chair of the treatment section of the European Academy of Allergology and Clinical Immunology/AAAAI/PRACTALL Consensus Group for atopic dermatitis. He has served on the Joint Task Force of the AAAAI/ACAAI for the 2004 and 2012 Practice Parameter for Atopic Dermatitis. He co-chaired the Expert Panel on Management of Moderate-to-Severe Atopic Dermatitis and chaired the Atopic Dermatitis Yardstick project.

Professor Boguniewicz's research focuses on immunopathogenesis and new treatments for atopic dermatitis. He is an investigator of the NIH Atopic Dermatitis Research Network. He has lectured at many national and international meetings and has over 350 peer-reviewed articles, reviews, chapters and abstracts published. He is the recipient of several Pediatric Allergy-Immunology Fellows Outstanding Teacher Award, the 2002 Faculty Clinician of the Year Award, the 2006 AAAAI's Richard S. Farr Memorial Lectureship, and has been selected for Best Doctors in America. He is also the recipient of the 2013 AAAAI Distinguished Clinician Award.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Associate Professor Dr Kaan Boztug MD**

Director, Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases

Director, Children's Cancer Research Institute / St Anna  
Kinderkrebsforschung

Head, Jeffrey Modell Expert Diagnostic and Research Center for  
Immunodeficiencies, Vienna , Austria.

Associate Professor Boztug studied Medicine in Düsseldorf, Freiburg and London, followed by his graduate training with Iain Campbell at the Scripps Research Institute (La Jolla, USA), clinical training and postgraduate research with Christoph Klein at Hannover Medical School (Germany).

He joined the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences in 2011 and holds a dual appointment as Associate Professor at the Department of Paediatrics and Adolescent Medicine at the Medical University of Vienna.

Associate Professor Boztug has been director of the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases since 2016. He is also director of the recently established CeRUD Vienna Center for Rare and Undiagnosed Diseases and joint director of the Jeffrey Modell Foundation Center for Immunodeficiencies at the Medical University of Vienna and St Anna Children's Hospital.

In his work, Associate Professor Boztug has identified various novel primary immunodeficiencies, including neutrophil disorders such as G6PC3 and JAGN1 deficiency, IL10R and IL21 deficiency as Mendelian types of early-onset inflammatory bowel disease, and deficiencies of PRKCD, NIK and DOCK2 causing combined immunodeficiency syndromes.

Associate Professor Boztug's travel is supported by an educational grant from CSL Behring.



# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Professor Mariana Castells MD PhD**

Brigham and Women's Hospital

Boston Massachusetts USA

Professor Castells is a clinician, researcher and teacher at Brigham and Women's Hospital and Dana Farber Cancer Institute, USA. She is the Director of the Drug Hypersensitivity and Drug Desensitization Center, as well as the Director of the Mastocytosis Center, and has served as the Allergy and Immunology Training Program Director for 20 years.

Professor Castells served on the Board of Directors of The American Academy of Allergy, Asthma & Immunology (AAAAI), and is now the research chair director of the AAAAI Foundation. She is on the Board of Directors for the ABAI, and the Board of Directors for the Journal of Allergy and Clinical Immunology (JACI) and the JACI In Practice. She is on the council of the International College of Allergy (CIA) and has directed the International Drug Desensitization Meeting (DDIM) in Barcelona, Spain, yearly.

Professor Castells has spearheaded the evaluation and understanding of drug anaphylaxis and hypersensitivity, and provided desensitization protocols which are used as standards around the world, treating thousands of patients with cancer and chronic inflammatory diseases, maintaining these patients on their first line therapy.

Her research has uncovered mast cell inhibitory mechanisms which are pertinent to desensitization. She has been involved in the new diagnostic criteria for mast cell activation disorders and mastocytosis and heads clinical trials created at the Mastocytosis Center.

Professor Castells' travel is supported by ASCIA.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Professor Timothy Craig MD DO**

Penn State University  
Allergy Asthma and Immunology  
Hershey, Pennsylvania USA

Professor Timothy Craig is a professor of medicine and pediatrics at Penn State University. He trained in the US Navy after which he started his academic career at the University of Iowa and then transferred to Penn State to start an Allergy and Immunology Program. He is the director of the Alpha-1-Deficiency Center at Penn State University.

Professor Craig is a distinguished educator, program director, section chief and a Fellow of the AAAAI, ACP, ACAAI and ACOI. He is the recipient of multiple teaching awards, has published over 250 manuscripts and has delivered over 350 invited lectures.

Professor Craig is proud to be a Vietnam Education Foundation Scholar.

Professor Craig's travel is supported by an educational grant from CSL Behring.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Professor Evan Dellon MD**

Gastroenterologist University of North Carolina, USA

Evan Dellon is a Professor of Medicine at the University of North Carolina School of Medicine. He joined the University of North Carolina (UNC) faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, in particular eosinophilic esophagitis (EoE). He became Director of CEDAS in 2014, and is an Associate Editor for *Clinical Gastroenterology and Hepatology*.

Professor Dellon's main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of eosinophilic esophagitis (EoE), and the eosinophilic GI diseases (EGIDs). He is widely published in this area, and collaborates with investigators all over the world. Dr. Dellon has received research funding from the National Institutes of Health, the American College of Gastroenterology, the American Gastroenterologic Association, the CURED Foundation (campaign urging research for eosinophilic disease), UNC, and a number of industry partners to study EoE and other EGIDs.

The goal of Professor Dellon's research is to improve the lives of patients with EoE and EGIDs by learning how to better diagnose, treat, and monitor the condition. He is widely published in this area, and collaborates with investigators all over the world.

Professor Dellon's travel for this conference is supported by Abbott.



# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Dr Tomaz Garcez MBChB FRCP FRCPath**

Consultant Immunologist at Manchester University NHS Foundation Trust (MFT), Manchester, United Kingdom

Dr Garcez graduated from Aberdeen University in 1997 and completed postgraduate general professional training in Cardiff (adult medicine) and higher specialist training in Bristol (immunology and general internal medicine).

Dr Garcez was appointed to Central Manchester University Hospitals NHS Foundation Trust (CMFT) as consultant immunologist in July 2011. He leads the clinical and laboratory immunology service in MFT, he is the elected Chair of the UK Primary Immunodeficiency Network (UKPIN) and holds a seat on the immunology and allergy Clinical Reference Group (CRG – NHS England).

Dr Garcez is a member of the medical advisory panel for PID UK and represented the Fatal Anaphylaxis Register on the Royal College of Anaesthetists National Audit Project 6 Steering Panel.

Dr Garcez represents the UK on the European Network for Drug Allergy Task Force on Perioperative Hypersensitivity and on an international collaboration exploring Perioperative Hypersensitivity.

Dr Garcez travel is supported by ANZAAG.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Associate Professor Matthew Greenhawt MD MBA MSc**

**Children's Hospital Colorado,  
University of Colorado School of Medicine  
Aurora, Colorado, USA**

Associate Professor Matthew Greenhawt earned his medical degree from Tufts University School of Medicine, Boston, Massachusetts. Subsequently, he completed a pediatrics residency at Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia Presbyterian Medical Center, New York, New York, and an allergy and clinical immunology fellowship at the University of Michigan in Ann Arbor, Michigan. He also holds an MBA from Tufts University and a master's of science degree in health and healthcare policy from the University of Michigan, Rackham School of Graduate Studies.

He is an Associate Professor with the Department of Pediatrics, Section of Allergy and Immunology at Children's Hospital Colorado and the University of Colorado School of Medicine. He serves as the director for the Children's Hospital Colorado Food Challenge and Research Unit.

Associate Professor Matthew Greenhawt is certified by the American Board of Pediatrics and American Board of Allergy and Immunology. He is a member of the American Academy of Allergy, Asthma & Immunology, American Academy of Pediatrics, American College of Allergy, Asthma & Immunology, and European Academy of Allergy and Clinical Immunology. He is an associate editor for the *Annals of Allergy, Asthma and Immunology*, and a member of the Joint Taskforce of Allergy Practice Parameters.

His research interests include establishment of phenotypes in food-allergic diseases, shared decision making, food allergy cost-effectiveness and comparative effectiveness research, food-allergic diseases health services and outcomes research, primary/secondary prevention and treatment of food allergy, and food allergy public policy. He has authored a number of peer-reviewed articles, abstracts, and book chapters. He serves as the current chair of the ACAAI Food Allergy Committee, and is a member of multiple AAAAI, ACAAI, and EAACI committees.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

International Keynote Speakers (in alphabetical order by surname)



## **Professor Peter Hellings MD**

Professor of Rhinology, The University of Amsterdam's Faculty of Medicine

In addition to his clinical work Professor Hellings is a researcher at the Clinical Immunology Laboratory. He is a member of the Flemish Agency for Care and Health, and has served as the Belgian representative in the European Academy of Facial Plastic Surgery. He is also the coordinator of the Excellence in Rhinoplasty course at KU Leuven since 2008.

Professor Peter Hellings conducts research into the mechanisms of chronic upper respiratory tract conditions, with a particular focus on allergic rhinitis and the non-allergic form that causes similar symptoms of stuffy nose and sneezing. A further area of interest is chronic rhinosinusitis, an inflammation of the mucous membrane in the nasal passage and sinuses, and in functional and aesthetic nasal problems.

Professor Hellings research spans the entire spectrum from animal research to in vitro and clinical studies. He has received various research grants and international awards for his scientific work. Hellings has also authored many articles in leading scientific journals including Nature, Lancet, Allergy, Journal of Allergy and Clinical Immunology, Journal of Clinical Investigation and Journal of Immunology.

Professor Helling's travel is supported by an educational grant from Mylan.



# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Professor Hugh A Sampson MD**

Icahn School of Medicine at Mount Sinai  
New York, USA

Professor Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine in New York and has nearly 35 years experience in translational research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders.

Professor Sampson's research has been funded continuously by grants from the National Institutes of Health (NIH), including the Principal Investigator for the Consortium for Food Allergy Research.

Professor Sampson has published over 500 articles, 88 book chapters and co-edited seven books, primarily on clinical and immunopathogenic aspects of food allergic disorders. He was elected to membership in the National Academy of Medicine of the National Academies in 2003 for his research accomplishments.

Professor Sampson is the past-president of the American Academy of Asthma, Allergy and Immunology (AAAAI), and served on the Board of the World Allergy Organization (WAO). He has trained over 40 post-doctoral allergy/immunology fellows, many of whom are now leaders in the field of food allergy. Professor Sampson has also served on the Editorial Board of five allergy journals, and is an Associate Editor of *Pediatric Allergy & Immunology*.

In November 2015, Professor Sampson stepped-down as Dean for Translational Biomedical Sciences at Mount Sinai to devote 40% of his time to DBV Technologies as their Chief Scientific Officer.

Professor Sampson's travel is supported by DBV Technologies.

# ASCIA 2019 CONFERENCE

30<sup>TH</sup> ANNUAL CONFERENCE OF THE AUSTRALASIAN SOCIETY OF CLINICAL IMMUNOLOGY AND ALLERGY (ASCIA)  
4-6 September 2019 | Perth Convention and Exhibition Centre | Perth | Western Australia

## International Keynote Speakers (in alphabetical order by surname)



### **Assistant Professor Carina Venter PhD**

University of Colorado Children's Hospital, Colorado USA

Dr Venter is Assistant Professor of Pediatrics, Section of Allergy and Immunology at the Children's Hospital Colorado and University of Colorado Denver School of Medicine, where she is conducting research and working with children and adults with a range of food allergies.

Assistant Professor Venter is a past chair of the International Network of Dietitians and Nutritionists in Allergy (INDANA), and a member of the American Academy of Allergy and Clinical Immunology (AAAAI), American College of Allergy and Clinical Immunology (ACAAI), European Academy of Allergy and Clinical Immunology (EAACI) and the British Society of Allergy and Clinical Immunology (BSACI). She was also a member of the NICE (UK) food allergy guidelines.

Assistant Professor Venter has had numerous publications in international journals, and has authored book chapters and edited a book on Food Hypersensitivity.

Assistant Professor Venter moved from the UK in 2015 where she had been performing research into food allergies and allergy prevention as a Senior Lecturer at the University of Portsmouth and at the David Hide Centre on the Isle of Wight.

One of the highlights of Assistant Professor Venter's career has been her appointment to the Expert Panel of the National Institutes for Allergy and Infectious Diseases Peanut Allergy Prevention Guidelines, making her the only dietitian that has had presentation on official US and European food allergy guidelines.

Assistant Professor Venter's travel is supported by Abbott.